Clinical Trial Update: Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer [NA]

View source ↗

Summary

The clinical trial NCT01789892 evaluating methylprednisolone before FDG-PET in lung cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• METHYLPREDNISOLONE (methylprednisolone)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Lung Cancer | NA | Status: WITHDRAWN